Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Mitsubishi Walks Away from Collategene Deal with AnGes
August 26, 2024
- GSK Introduces Asthma Drug Relvar for Children in Japan
August 26, 2024
- A Time for Patience - 3: As iPSC-Based Drug Discovery Advances, Will 2 Existing Meds Be Repurposed for ALS?
August 26, 2024
- UK OKs Eisai’s Alzheimer’s Drug, but Health Coverage Nixed
August 26, 2024
- Moderna’s JN.1-Tailored COVID Vaccine Approved in Japan
August 26, 2024
- A Time for Patience - 2: Will High-Dose Mecobalamin and Tofersen Become First-Line Treatments in ALS?
August 23, 2024
- Xolair SC Pen Versions Go on Sale in Japan: Novartis
August 23, 2024
- Leqembi Approved in UK: Eisai
August 23, 2024
- Bayer Japan Says No Job Cuts to Soothe Employees’ Nerves as Xarelto Generics Loom
August 23, 2024
- Lilly’s BTK Inhibitor Jaypirca Hits Japan Market for MCL
August 22, 2024
- A Time for Patience - 1: New Drugs for ALS Emerging, Some Close to Approval; Can They Meet Unmet Needs?
August 22, 2024
- Rakuten Medical Japan VP Kodama Promoted to President
August 22, 2024
- Keytruda Regains Top-Selling Status in Japan in April-June: IQVIA
August 21, 2024
- Padcev Approved for Bladder Cancer in China: Astellas
August 21, 2024
- GSK’s Consumer Unit in Japan to Rebrand as Haleon in September
August 20, 2024
- Bayer Set to Finally List Xarelto AG in December, Espha as Distributor
August 20, 2024
- Enhertu Bags Breakthrough Therapy Tag for HER2 Low or Ultralow Breast Cancer
August 20, 2024
- Enhertu Grabs Conditional Nod for Gastric Cancer in China: Daiichi Sankyo
August 20, 2024
- Cheplapharm Snags 2 More Brands from Clinigen in Japan
August 20, 2024
- Otsuka Rolls Out Therapeutic App for Depression in US
August 19, 2024
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…